Search for: "AstraZeneca Pharmaceuticals LP" Results 81 - 100 of 116
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
16 May 2012, 12:22 pm by Bexis
AstraZeneca Pharmaceuticals, LP, 634 F.3d 1352, 1360-66 (11th Cir. 2011) (plaintiff had not pleaded recoverable economic injury); Polk v. [read post]
26 Jan 2011, 1:31 am by Ben Vernia
In April of last year, we obtained a $520 million settlement with AstraZeneca LP and AstraZeneca Pharmaceuticals LP to resolve allegations that marketing of the anti-psychotic drug Seroquel for uses not approved as safe and effective by the FDA caused false claims to be submitted to federal health care programs. [read post]
Astrazeneca Pharmaceutical LP held a leave of absence or a leave extension can constitute a reasonable accommodation under the ADA “in some circumstances”, although in that case ultimately concluded the plaintiff could not show her request for twelve additional months of leave was facially reasonable. [read post]
16 Apr 2012, 1:29 am by FDABlog HPM
District Court are Motions for Summary Judgment filed by FDA and AstraZeneca Pharmaceuticals LP (here and here) concerning FDA’s approval of ANDAs for generic versions of SEROQUEL (quetiapine fumarate) Tablets and the Agency’s decision, discussed in a March 27, 2012 Letter Decision, concerning the scope and applicability of 3-year marketing exclusivity in that case. [read post]
Astrazeneca Pharmaceutical LP held a leave of absence or a leave extension can constitute a reasonable accommodation under the ADA “in some circumstances”, although in that case ultimately concluded the plaintiff could not show her request for twelve additional months of leave was facially reasonable. [read post]
10 Sep 2012, 7:28 pm by FDABlog HPM
In July, after a court battle with FDA that started around mid-March when AstraZeneca Pharmaceuticals LP (“AstraZeneca”) sought to enjoin FDA from granting final ANDA approvals for generic SEROQUEL following FDA’s denial (without comment) of two citizen petitions AstraZeneca submitted to FDA last year concerning labeling carve-out issues, the U.S. [read post]
13 Nov 2014, 5:00 am
  Such vaccine litigation (Bexis’ first exposure to a pharmaceutical mass tort) was ultimately adjudged so inimical to the public health that Congress prohibited it. [read post]
6 May 2017, 10:11 am by Lawrence B. Ebert
(“Braintree”) appealsfrom the Southern District of New York’s summary judgmentthat Breckenridge Pharmaceutical, Inc. [read post]
23 Jul 2009, 3:15 am
Astrazeneca Pharmaceuticals LP), because of Bexis' firm's involvement in the litigation (although not this aspect). [read post]
29 Feb 2008, 8:00 am
– Teva’s opposition proceedings regarding IL 130424 to Pfizer: (IP Factor), Thailand: Thai chief drug price negotiator removed from post: (GenericsWeb), Thailand: Compulsory licences cannot be revoked: (Generic Pharmaceuticals & IP), (more from Generic Pharmaceuticals & IP), UK: Court of Appeal for England and Wales hands down decision in Boehringer Ingelheim KG and Boehringer Ingelheim Pharma KG v Swingward Limited relating to repackaging… [read post]
18 Mar 2024, 9:46 am by Kalvis Golde
AstraZeneca Pharmaceuticals, LP 23-665Issue: Whether, where an unemployment applicant’s religious beliefs are independently sufficient to cause her refusal to follow an employer policy, a state can deny her unemployment benefits by holding that philosophical and personal beliefs outweigh her religious beliefs. [read post]
19 Sep 2013, 9:53 am by Bexis
The following post is exclusively the work of the Reed Smith side of the blog.Sometimes the smallest, least significant type of lawsuit can illustrate cracks in the edifice of the largest, most consequential litigation. [read post]